Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Dong-A ST Co., Ltd.
  6. News
  7. Summary
    A170900   KR7170900005

DONG-A ST CO., LTD.

(A170900)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dong-A and Pharmasyntez Consider Joint Venture for Russian Drug Manufacture

04/12/2017 | 10:38am EST

Dong-A has signed a memorandum for a strategic partnership with Pharmasyntez for the Russian manufacture of Dong-A's innovative drugs at Russian Pharmasyntez facilities. The two companies are also considering the formation of a joint venture (JV) for manufacturing drugs on Russian territory, with the aim of backing the government's import substitution strategy to reduce reliance on foreign imports. The new agreement, and the JV, if finalised, should facilitate the manufacture of a range of important pharma products on Russian soil, theoretically reducing costs for the government of essential drugs, and ensuring an uninterrupted supply for the population.


ę S&P Capital IQ 2017
All news about DONG-A ST CO., LTD.
11/02Antiva Biosciences, Inc. announced that it has received $31 million in funding from a g..
CI
10/25Antiva Biosciences, Inc. announced that it expects to receive funding
CI
07/22Intas Pharmaceuticals Limited Enters into an Exclusive License Agreement with Meiji and..
CI
02/08Dong-A ST Co., Ltd. Completes the Proof-Of-Concept Study for ĹDA-1241,’ an Investigatio..
CI
2020DONG-A ST CO., LTD.(KOSE : A170900) dropped from KOSPI 200 Index
CI
2019Dong-A ST and Beactica Therapeutics Achieve Key Milestone in Their Collaboration to Dev..
CI
2018Neurobo Pharma Enters into Licensing Agreement with Dong-A ST
CI
2017Dong-A and Pharmasyntez Consider Joint Venture for Russian Drug Manufacture
CI
2017Dong-A ST Co., Ltd. Enters into License Agreement with AbbVie, Inc
CI
2016ST Pharm Co.,Ltd. cancelled the acquisition of Banwol Factory from Dong-A ST Co., Ltd..
CI
More news
Financials
Sales 2021 601 B 0,51 B 0,51 B
Net income 2021 27,4 B 0,02 B 0,02 B
Net cash 2021 32,7 B 0,03 B 0,03 B
P/E ratio 2021 21,9x
Yield 2021 1,42%
Capitalization 593 B 497 M 499 M
EV / Sales 2021 0,93x
EV / Sales 2022 0,82x
Nbr of Employees 1 612
Free-Float 61,3%
Chart DONG-A ST CO., LTD.
Duration : Period :
Dong-A ST Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DONG-A ST CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 70 300,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dae-Sik Eom Chief Executive Officer & Director
Hyeong-Heon Kim Head-Compliance Support
Geun-Soo Kim Independent Director
Jae-Sang Ryu Independent Director
Hui-Joo Choi Independent Director
Sector and Competitors